Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. (Q38075796)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

review article

1 reference

title

Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Akihiro Tamori

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Shuhei Nishiguchi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Norifumi Kawada

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

22 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

999-1005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B Virus Infection

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0742-5

Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B

21 January 2018

1 reference

12 December 2020

Management of HBV infection in Japan

1 reference

12 December 2020

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B

1 reference

12 December 2020

Hepatitis B virus genotypes and response to antiviral therapy.

1 reference

12 December 2020

Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus

1 reference

12 December 2020

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

12 December 2020

Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B

1 reference

12 December 2020

10.1007/S00535-012-0742-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23338486%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference